Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Helse Bergen HF
Sponsor

Helse Bergen HF

Norway Haukelandsveien 22, 5021 Bergen, Norway

About the sponsor

Clinical research includes acute myeloid leukemia, high-risk myelodysplastic syndrome, breast cancer, pancreatic cancer, and recurrent grade IV glioma. The funded studies also address treatment response, resistance, and survival in aggressive cancer settings.

  • Acute myeloid leukemia
  • Breast cancer
  • Pancreatic cancer
  • Recurrent grade IV glioma

Research activity spans both solid tumours and blood cancers, with interest in personalised treatment strategies and disease control in difficult-to-treat malignancies.

About Specializations

Helse Bergen HF runs clinical trials in conditions such as Multiple sclerosis, Chronic fatigue syndrome, Cluster headache, Breast cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

26 clinical trials

Epstein-Barr virus infection

Recruiting

Safety and Tolerability of Tenofovir Alafenamide Dose Escalation in Healthy Adults for Epstein‑Barr Virus Infection

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tenofovir Alafenamide
  • Sponsor:Helse Bergen HF

Crohn's disease

Recruiting

Study on Using Ultrasound with Perflubutane and Laxative for Detecting Crohn's Disease in Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Macrogol 3350
  • Sponsor:Helse Bergen HF

Chronic fatigue syndrome

Recruiting

Study on Daratumumab for Reducing Symptoms in Patients with Moderate to Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Daratumumab
  • Sponsor:Helse Bergen HF

Malignant glioma

Recruiting

Study on Bortezomib and Temozolomide for Patients with Recurrent Grade IV Glioma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Helse Bergen HF

Hyperadrenocorticism+1

Recruiting

Study on Metyrapone for Patients with Mild Autonomous Cortisol Secretion

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Metyrapone
  • Sponsor:Helse Bergen HF

Drug use disorder

Recruiting

Study on Dexamfetamine for Adults with Amphetamine and Opioid Dependence Undergoing Opioid Treatment

Investigational
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Dexamfetamine Sulfate
  • Sponsor:Helse Bergen HF

Multiple sclerosis

Recruiting

Study on the Use of Mesenchymal Stem Cells and Sodium Chloride for Patients with Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Helse Bergen HF

Endocrine ophthalmopathy

Recruiting

Study Comparing Sirolimus and Methylprednisolone for Patients with Active Thyroid Eye Disease

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Helse Bergen HF

Acute myeloid leukaemia

Recruiting

Study on Hydroxyurea and Valproic Acid or 6-Mercaptopurine with Valproic Acid for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Hydroxycarbamide
  • Sponsor:Helse Bergen HF

Multiple sclerosis

Recruiting

Comparison of ocrelizumab and rituximab treatment in adults with active relapsing-remitting multiple sclerosis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Helse Bergen HF

Deafness neurosensory

Recruiting

Study of Hyperbaric Oxygen Therapy Combined with Standard Treatment for Patients with Sudden Hearing Loss

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nitrous Oxide
  • Sponsor:Helse Bergen HF

Metabolic disorder

Recruiting

Study on Semaglutide for Weight Control in Patients with Schizophrenia and High BMI Using Antipsychotics

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Helse Bergen HF

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.